Preventing IgA nephropathy flare-ups with Nefecon
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether continuing Nefecon after initial treatment helps prevent IgA nephropathy (a kidney disease) from coming back. If you have already been on Nefecon for at least 9 months and your protein levels are low now, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgA nephropathy through a kidney biopsy.
- You are at least 18 years old.
- You have been taking Nefecon (16 mg daily) for at least 9 months.
- Before starting Nefecon, you had high protein in your urine (at least 1 gram per day).
- Currently, your urine protein is below 0.5 grams per day.
- Your kidney function (measured by eGFR) is at least 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.